Halozyme Therapeutics | HALO - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Amarin USD 3K 5K 2024-12
Amgen USD 95.64B 94.98B 2026-06
Baxter International USD 78M 20M 2026-03
Cara Therapeutics -89.64M 128.67M 2025-12
Cytokinetics USD 34.83M 1.5M 2026-06
DBV Technologies USD 461K 323.71K 2025-03
Eli Lilly USD 114.7M 134.3M 2025-09
Halozyme Therapeutics USD 5.59M 80K 2026-06
Intrexon USD 2K 5K 2024-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
MannKind USD 14.82M 2.38M 2026-06
Minerva Neurosciences USD 2.31M 60K 2024-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Pfizer USD 667M 4M 2026-06
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
United Therapeutics USD 2.9M 200K 2026-06
Vanda Pharmaceuticals -1.37B 1.97B 2025-12